{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:45:39Z","timestamp":1792601139094,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119452","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:24:07Z","timestamp":1792509847000},"page":"119452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Structural analysis and crystallography-guided pharmacophore elucidation of capmatinib analogues as selective c-MET targeting anticancer agents"],"prefix":"10.1016","volume":"321","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-3743","authenticated-orcid":false,"given":"Mehdi","family":"Valipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119452_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119452_bib2","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119452_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000512218","article-title":"Epithelial-mesenchymal transition (EMT) as a therapeutic target","volume":"211","author":"Jonckheere","year":"2022","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.ejmech.2026.119452_bib4","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3390\/ijms25116109","article-title":"MET oncogene targeting for cancer immunotherapy","volume":"25","author":"Lombardi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119452_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/ccs3.70075","article-title":"Hepatocyte growth factor\/c\u2010Met signaling axis in human diseases: mechanistic insights and therapeutic potential","volume":"20","author":"Sun","year":"2026","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2026.119452_bib6","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.3390\/ijms25169101","article-title":"Unveiling the role of HGF\/c-Met signaling in non-small cell lung cancer tumor microenvironment","volume":"25","author":"Yao","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119452_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41392-026-02682-9","article-title":"C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy","volume":"11","author":"Zhu","year":"2026","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119452_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/cancers13051115","article-title":"Resistance to molecularly targeted therapies in melanoma","volume":"13","author":"Patel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119452_bib9","first-page":"13","article-title":"c-Met as a target for personalized therapy","volume":"7","author":"Garajov\u00e1","year":"2015","journal-title":"Transl. Oncogenomics"},{"key":"10.1016\/j.ejmech.2026.119452_bib10","article-title":"Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1, 2, 4-triazine moieties as potential c-MET targeting anticancer agents","author":"Khatir","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12935-022-02658-z","article-title":"Anti-cancer therapeutic strategies based on HGF\/MET, EpCAM, and tumor-stromal cross talk","volume":"22","author":"Barzaman","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2026.119452_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/biomedicines2040359","article-title":"Monoclonal antibodies against the MET\/HGF receptor and its ligand: multitask tools with applications from basic research to therapy","volume":"2","author":"Prat","year":"2014","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119452_bib13","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1021\/jm401427c","article-title":"Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress","volume":"57","author":"Cui","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117177","article-title":"Advances in the selective c-MET kinase inhibitors: application of fused [5, 6]-Bicyclic nitrogen-containing cores for anticancer drug design","volume":"284","author":"Valipour","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/17460441.2023.2246881","article-title":"The current role and evolution of X-ray crystallography in drug discovery and development","volume":"18","author":"Bijak","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119452_bib16","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/s41598-024-52018-2","article-title":"Fragment library screening by X-ray crystallography and binding site analysis on thioredoxin glutathione reductase of Schistosoma mansoni","volume":"14","author":"de Souza Neto","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119452_bib17","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/jm800043g","article-title":"Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase","volume":"51","author":"Albrecht","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib18","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1016\/j.bmcl.2009.09.096","article-title":"Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors","volume":"19","author":"Boezio","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119452_bib19","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1158\/1535-7163.MCT-09-0477","article-title":"SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo","volume":"8","author":"Buchanan","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119452_bib20","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib21","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1021\/jm400926x","volume":"56","author":"Cui","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib22","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1021\/jm501913a","article-title":"Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors","volume":"58","author":"Peterson","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib23","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1021\/acs.jmedchem.5b01716","article-title":"A potent and selective inhibitor of MET with high unbound target coverage and robust in vivo antitumor activity","volume":"59","author":"Boezio","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejmech.2016.03.076","article-title":"Discovery of 6-(difluoro (6-(4-fluorophenyl)-[1, 2, 4] triazolo [4, 3-b][1, 2, 4] triazin-3-yl) methyl) quinoline as a highly potent and selective c-Met inhibitor","volume":"116","author":"Zhan","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib25","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/acsmedchemlett.9b00276","article-title":"Structural and molecular insight into resistance mechanisms of first generation cMET inhibitors","volume":"10","author":"Collie","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119452_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s42003-025-07490-5","article-title":"Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer","volume":"8","author":"Lin","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2026.119452_bib27","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acsmedchemlett.5c00713","article-title":"Molecular basis of c-MET inhibition by approved small molecule drugs: a structural perspective","volume":"17","author":"Russell","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119452_bib28","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1021\/jm502018y","article-title":"Design and optimization of a series of 1-sulfonylpyrazolo [4, 3-b] pyridines as selective c-Met inhibitors","volume":"58","author":"Ma","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bioorg.2016.02.009","article-title":"Design, synthesis and biological evaluation of 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as c-Met inhibitors","volume":"65","author":"Liu","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1021\/ml5004876","article-title":"Design, synthesis, and biological evaluation of novel imidazo [1, 2-a] pyridine derivatives as potent c-Met inhibitors","volume":"6","author":"Li","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119452_bib31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/aps.2016.11","article-title":"Discovery of a new series of imidazo [1, 2-a] pyridine compounds as selective c-Met inhibitors","volume":"37","author":"Liu","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119452_bib32","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1016\/j.bmcl.2011.09.066","article-title":"Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors","volume":"21","author":"Ryu","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119452_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bioorg.2016.12.002","article-title":"Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: synthesis, SAR study, and biological activity","volume":"70","author":"Yang","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib34","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.23.02363","article-title":"Vebreltinib for advanced non\u2013small cell lung cancer harboring c-Met exon 14 skipping mutation: a multicenter, Single-Arm, phase II KUNPENG study","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119452_bib35","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-24-1726","article-title":"Antitumor activity of vebreltinib and characterization of clinicogenomic features in solid tumors with MET rearrangements","volume":"15","author":"Nakazawa","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119452_bib36","doi-asserted-by":"crossref","first-page":"6880","DOI":"10.1158\/0008-5472.CAN-10-0898","article-title":"MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor\u2013dependent fashion to suppress carcinoma growth","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119452_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41392-023-01403-w","article-title":"SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer","volume":"8","author":"Zhou","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119452_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT127","article-title":"Abstract CT127: a phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations","volume":"80","author":"Yang","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119452_bib39","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"Jia","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib40","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/cmdc.201200145","article-title":"O\u2010linked triazolotriazines: potent and selective c\u2010Met inhibitors","volume":"7","author":"Chen","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119452_bib41","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.bmcl.2005.12.037","article-title":"8-Fluoroimidazo[1,2-a]pyridine: synthesis, physicochemical properties and evaluation as a bioisosteric replacement for imidazo[1,2-a]pyrimidine in an allosteric modulator ligand of the GABAA receptor","volume":"16","author":"Humphries","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119452_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/jm900817u","article-title":"Three-dimensional pharmacophore methods in drug discovery","volume":"53","author":"Leach","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119452_bib43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-10-1623","article-title":"Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors","volume":"71","author":"Qi","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119452_bib44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.21037\/jtd-2026-0949","article-title":"Research progress on resistance and mechanisms of c-Met inhibitors in treating MET exon 14 skipping mutant non-small cell lung cancer: a narrative review","volume":"18","author":"Bu","year":"2026","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejmech.2026.119452_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70338","article-title":"Responsiveness of different MET tumour alterations to type I and type II MET inhibitors","volume":"15","author":"Murciano\u2010Goroff","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119452_bib46","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","article-title":"Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer","volume":"6","author":"Bahcall","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119452_bib47","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1021\/acs.jcim.3c00429","article-title":"Molecular insights on the conformational transitions and activity regulation of the c-Met kinase induced by ligand binding","volume":"63","author":"Liu","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119452_bib48","series-title":"The Conformational Heterogeneity of MET and its Role in Inhibitor Recognition, Autoinhibition and Activation","author":"Baker","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119452_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2017.11.073","article-title":"Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors","volume":"143","author":"Yuan","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:25:56Z","timestamp":1792599956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":49,"alternative-id":["S0223523426008974"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119452","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural analysis and crystallography-guided pharmacophore elucidation of capmatinib analogues as selective c-MET targeting anticancer agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119452"}}